Instruction 1(b).

FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject
to Section 16. Form 4 or Form 5
obligations may continue. See

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Shendelman Shoshana						2. Issuer Name and Ticker or Trading Symbol Applied Therapeutics Inc. [ APLT ]								S. Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director X 10% Owner  Officer (give title Check (specify))						
(Last) (First) (Middle) C/O APPLIED THERAPEUTICS, INC. 545 FIFTH AVENUE, SUITE 1400						3. Date of Earliest Transaction (Month/Day/Year) 12/14/2021								X Officer (give title Other (specify below)  President and CEO						
(Street) NEW YO	reet) EW YORK NY 10017				4. If Amendment, Date of Original Filed (Month/Day/Year) 12/16/2021								G. Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person							
(City)	(Si		Zip)																	
Table I - Non-Deriva:  1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/N				on	on 2A. Deemed Execution Date,			quired, Disposed of, or 3.  3.				Acquired (A) or			5. Amount of Securities Beneficially Owned Following		nership : Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) o	Pric	ce	Reported Transaction(s) (Instr. 3 and 4)			,	(Instr. 4)	
Common	Stock			12/14/20	)21				A		120,900(1)	A	\$(	0.00	485	5,186		D		
Common	Stock														1,75	0,000		I	See footnote <sup>(2)</sup>	
Common	Stock														1,49	2,094		I	See footnote <sup>(3)</sup>	
Common Stock														709,720			I	See footnote <sup>(4)</sup>		
Common Stock														290,280			I	See footnote <sup>(5)</sup>		
Common Stock														88,397			I	See footnote <sup>(6)</sup>		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	ve Conversion Date Execution Date, or Exercise (Month/Day/Year) if any			Transaction Code (Instr. 8)  Derivati Securiti Acquire (A) or Dispose of (D) (Instr. 3) and 5)		vative rities nired r osed ) r. 3, 4	Expira	ation D h/Day/	Year)	7. Title and Amount of Securities Underlying Derivative Security (Inst: 3 and 4)  Amour or Numbe of Title Shares		tr.	. Price of derivative security nstr. 5)  Beneficia Owned Followin Reported Transact (Instr. 4)		e s ally g	10. Ownersh Form: Direct (D or Indirec (I) (Instr.	Beneficial Ownership ct (Instr. 4)			

## **Explanation of Responses:**

- 1. Consists of compensatory Restricted Stock Units granted under Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan. Each compensatory Restricted Stock Unit represents a contingent right to receive one share of the issuer's common stock. One-fourth (1/4th) of the compensatory Restricted Stock Units shall vest on December 14, 2022, and one-twelfth (1/12th) of the remaining shares subject to the compensatory Restricted Stock Units shall vest each quarter thereafter, subject to the Reporting Person continuing to provide services through each such date.
- 2. Through a grantor retained annuity trust.
- 3. Through a family trust controlled by the reporting person's spouse.
- 4. Through the reporting person's spouse.
- 5. Through a family trust controlled by the reporting person.
- 6. Through Clearpoint Strategy Group LLC of which the reporting person is the sole owner.

## Remarks:

This amendment is being filed solely to correct the vesting schedule for the compensatory Restricted Stock Units reported on the Reporting Person's Form 4 filed on December 16, 2021.

/s/ Shoshana Shendelman 01/11/2022

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.